
The European Commission approved AbbVie’s merger with Allergan on the condition the companies sell off Allergan’s late-stage IL-23 inhibitor brazikumab. That stipulation is far from a deal-breaker; Allergan already offered to offload the med, which the EU claimed conflicted with AbbVie’s IL-23 candidate risankizumab, along with cystic fibrosis med Zenpep.
In forcing Allergan to give up brazikumab, the EU aims to avoid antitrust concerns in the irritable bowel disease market.
“Our decision makes sure that the merger between AbbVie and Allerganwill not disrupt the development of a promising innovative treatment for these diseases,” said Margrethe Vestager, executive VP of EU Merger Regulation.
Although a final decision from the Federal Trade Commission (FTC) has yet to come, the EU approval gives the first go-ahead to a megamerger expected to create the fourth-largest drugmaker in the world. In September, the FTC sent a “second request” for information on the deal to both drugmakers, giving hope to a coalition of unions and consumer groups that had asked the agency to “carefully examine” the deal and block it outright if necessary.
Full Content: Europa Press
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Trump’s Latest Order Seeks Greater Control Over Federal Regulators
Feb 19, 2025 by
CPI
Germany’s Competition Watchdog Urges Tighter Controls on Oil Prices
Feb 19, 2025 by
CPI
Equifax Must Face Suit Over Alleged Market Monopolization
Feb 19, 2025 by
CPI
Public Interest Groups Push for Rehearing on FCC Net Neutrality Case
Feb 18, 2025 by
CPI
Australian Regulator Backs Virgin Australia-Qatar Airways Alliance
Feb 18, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Criminal Enforcement
Jan 23, 2025 by
CPI
The Antitrust Division’s Recent Work to Combat International Cartels
Jan 23, 2025 by
Emma Burnham & Benjamin Christenson
Information Sharing: The New Frontier of U.S. Antitrust Enforcement
Jan 23, 2025 by
Brian P. Quinn, Casey Kovarik & Michael Tubach
The Key Role of Guidelines on Exchanges of Information Among Competitors and the Divergent Transatlantic Paths
Jan 23, 2025 by
Rosa Abrantes-Metz & Albert Metz
Leniency, Whistleblowers, and Compliance
Jan 23, 2025 by
Richard Powers, Tara O’Malley & Cory Gordon